A Phase 1/2 interventional study of Placebo and Pregabalin in Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 18 sites in 3 countries. Open to participants aged 1 Month to 16 Years. Per ClinicalTrials.gov, last updated 2021-02-11.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing pregabalin in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsies, Partial.
Among the 18 studies testing pregabalin in Epilepsies, Partial, this one is the 15th largest by enrollment, is one of 5 that started in 2007, is the only one in phase 1/2, and was the 10th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 18 studies testing pregabalin in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 1 Month to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 12 · Phase 4 4
First in 1997; this study’s year is marked. 5 started in 2007.
This study's enrollment of 65 is below the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 244 across the 18 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 18 have an industry lead sponsor. The 3 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
15 studies in Epilepsies, Partial by Viatris Inc.: none open now, none under way, none of them phase 3. Of 15 finished, 15 (100%) have results posted.
Among the 15 studies in Epilepsies, Partial by Viatris Inc., this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is one of 7 that started in 2007, is the only one in phase 1/2, and was the 4th registered.
Viatris Inc.’s Epilepsies, Partial studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing pregabalin in Epilepsies, Partial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 15 in Epilepsies, Partial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of pregabalin in pediatric patients with partial onset seizures that are incompletely controlled on their current medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Placebo
Drug: Pregabalin
Placebo
Orally-administered pregabalin
Number of Treatment-Emergent Adverse Events (AEs) by Severity: Double-blind Treatment
Analysis for severity of AEs was performed separately for double-blind and open-label treatment. AE = any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. AEs were classified as mild, moderate and severe based on severity assessment: Mild = no interference with participant's usual function; Moderate = some interference with participant's usual function; Severe = significant interference with participant's usual function. Treatment-emergent events for double-blind treatment included events between baseline and Day 7 that were absent before treatment or that worsened relative to pretreatment state. Participants may experience more than 1 AE.
Time frame: Baseline to Day 7
Number of Treatment-Emergent Adverse Events (AEs) by Severity: Open-label Treatment
Analysis for severity of AEs was performed separately for double-blind and open-label treatment. AE = any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. AEs were classified as mild, moderate and severe based on severity assessment: Mild = no interference with participant's usual function; Moderate = some interference with participant's usual function; Severe = significant interference with participant's usual function. Treatment-emergent events for open-label treatment included events between Day 8 and 28 days after the open-label dose that were absent before treatment or that worsened relative to pretreatment state. Participants may experience more than 1 AE.
Time frame: Day 8 up to 28 days after open-label dose of study medication
Number of Participants With Clinically Significant Change in Physical and Neurological Findings
Full physical examination included examination of the abdomen, breasts, lungs, lymph nodes, mouth, genitourinary, musculoskeletal and neurological systems, skin, extremities, head, heart, ears, eyes, neck, nose, ocular fundi, throat and thyroid gland. The neurological exam was performed by a pediatric neurologist or qualified investigator.
Time frame: Baseline up to 7 days post-last dose of study medication
28-Day Seizure Frequency Rate
Seizure frequency was reported by participant's parent or guardian from randomization to 7 days post-last dose of study medication. 28-day seizure frequency rate = (number of seizures in observation period/number of days in observation period)\*28.
Time frame: Baseline up to 7 days post-last dose of study medication
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau): Multiple-Dose Analysis
Area under the curve from time zero to the end of dosing interval (AUCtau), where dosing interval was 12 hours, for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants). Results are normalized to individual participant's Day 8 dose.
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12 hours post-dose on Day 8
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]: Single-Dose Analysis
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants). Results are normalized to individual participant's Day 8 dose.
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Maximum Observed Plasma Concentration (Cmax): Multiple-Dose Analysis
Cmax for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants). Results are normalized to individual participant's Day 8 dose.
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Maximum Observed Plasma Concentration (Cmax): Single-Dose Analysis
Cmax for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants). Results are normalized to individual participant's Day 8 dose.
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Time to Reach Maximum Observed Plasma Concentration (Tmax): Multiple-Dose Analysis
Tmax for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Time to Reach Maximum Observed Plasma Concentration (Tmax): Single-Dose Analysis
Tmax for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants).
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Plasma Decay Half-Life (t1/2): Multiple-Dose Analysis
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. t1/2 for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Plasma Decay Half-Life (t1/2): Single-Dose Analysis
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. t1/2 for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants).
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Apparent Oral Clearance (CL/F): Multiple-Dose Analysis
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL/F for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Apparent Oral Clearance (CL/F): Single-Dose Analysis
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL/F for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants).
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 hours post-dose on Day 8
Renal Clearance (CLr): Multiple-Dose Analysis
Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time. CLr for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).
Time frame: 0 to 12 hours post-dose, 12 to 24 hours post-dose on Day 8
Renal Clearance (CLr): Single-Dose Analysis
Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time. CLr for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning was to be reported (single-dose participants).
Time frame: 0 to 12 hours post-dose, 12 to 24 hours post-dose on Day 8
| Milestone | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Placebo (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Placebo (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Placebo (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) | Placebo (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 5 | 3 | 3 | 2 | 3 | 5 | 3 | 3 | 4 | 2 | 3 |
| Completed | 3 | 3 | 3 | 2 | 4 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 2 | 2 | 4 | 3 | 3 | 4 | 1 | 2 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Full physical examination included examination of the abdomen, breasts, lungs, lymph nodes, mouth, genitourinary, musculoskeletal and neurological systems, skin, extremities, head, heart, ears, eyes, neck, nose, ocular fundi, throat and thyroid gland. The neurological exam was performed by a pediatric neurologist or qualified investigator.
| participants | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Placebo (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Placebo (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Placebo (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) | Placebo (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Change in Physical and Neurological Findings | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
Analysis for severity of AEs was performed separately for double-blind and open-label treatment. AE = any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. AEs were classified as mild, moderate and severe based on severity assessment: Mild = no interference with participant's usual function; Moderate = some interference with participant's usual function; Severe = significant interference with participant's usual function. Treatment-emergent events for double-blind treatment included events between baseline and Day 7 that were absent before treatment or that worsened relative to pretreatment state. Participants may experience more than 1 AE.
| adverse events | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Placebo (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Placebo (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Placebo (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) | Placebo (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mild | 0 | 2 | 2 | 4 | 1 | 1 | 4 | 5 | 5 | 13 | 0 | 3 | 3 | 5 | 2 | 0 | 2 | 11 | 2 | 0 |
| Moderate | 1 | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 2 | 0 | 1 | 1 | 4 | 3 | 0 |
| Severe | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 0 |
Seizure frequency was reported by participant's parent or guardian from randomization to 7 days post-last dose of study medication. 28-day seizure frequency rate = (number of seizures in observation period/number of days in observation period)\*28.
No measurements were reported for this outcome.
Area under the curve from time zero to the end of dosing interval (AUCtau), where dosing interval was 12 hours, for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants). Results are normalized to individual participant's Day 8 dose.
| (microgram*hour/milliliter)/(mg/kg) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau): Multiple-Dose Analysis | 7.614 ± 19 | 7.563 ± 26 | 7.595 ± 6 | NA ± NA | 7.962 ± 29 | NA ± NA | NA ± NA | 8.203 ± 31 | 11.64 ± 29 | 9.571 ± 9 | 7.59 | NA ± NA | 10.20 ± 13 | 13.07 ± 34 | 9.642 ± 44 | 14.4 |
AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants). Results are normalized to individual participant's Day 8 dose.
| (microgram*hour/milliliter)/(mg/kg) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]: Single-Dose Analysis | 6.70 | 8.10 | 7.05 | 7.02 | 8.30 | 6.38 | 8.76 | 9.16 | 10.0 | 10.1 | 8.00 | 15.9 | 13.8 | 10.6 | — | — |
Cmax for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants). Results are normalized to individual participant's Day 8 dose.
| (microgram/milliliter)/(mg/kg) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax): Multiple-Dose Analysis | 1.468 ± 23 | 1.577 ± 11 | 1.496 ± 14 | NA ± NA | 1.601 ± 13 | NA ± NA | NA ± NA | 1.856 ± 15 | 2.350 ± 29 | 1.660 ± 13 | 0.945 | NA ± NA | 1.762 ± 22 | 2.538 ± 44 | 1.355 ± 59 | 1.94 |
Cmax for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants). Results are normalized to individual participant's Day 8 dose.
| (microgram/milliliter)/(mg/kg) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax): Single-Dose Analysis | 1.51 | 1.81 | 1.18 | 1.52 | 1.93 | 1.50 | 1.70 | 1.54 | 1.31 | 2.29 | 1.24 | 1.28 | 1.81 | 1.79 | — | — |
Tmax for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).
| hours | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax): Multiple-Dose Analysis | 0.617 (0.500 to 1.00) | 1.05 (1.00 to 2.08) | 1.12 (1.02 to 2.00) | 2.49 (0.967 to 4.02) | 0.500 (0.500 to 2.00) | 1.67 (1.17 to 2.17) | 2.62 (1.17 to 4.07) | 1.00 (0.967 to 1.17) | 0.583 (0.583 to 1.00) | 1.00 (1.00 to 1.00) | 4.00 | 0.790 (0.500 to 1.08) | 0.500 (0.500 to 4.00) | 0.583 (0.483 to 1.00) | 2.09 (1.50 to 8.08) | 2.15 |
Tmax for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants).
| hours | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax): Single-Dose Analysis | 1.00 | 0.967 | 1.13 | 1.00 | 0.450 | 1.00 | 1.00 | 1.98 | 1.00 | 0.583 | 2.00 | 4.00 | 4.05 | 1.00 | — | — |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. t1/2 for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).
| hours | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plasma Decay Half-Life (t1/2): Multiple-Dose Analysis | 4.433 ± 0.17559 | 3.397 ± 0.58603 | 3.263 ± 0.49903 | NA ± NA | 3.90 | NA ± NA | 3.523 ± 0.25146 | 3.520 ± 0.91804 | 4.287 ± 0.27737 | 4.113 ± 0.25891 | NA ± NA | NA ± NA | 4.960 ± 1.3857 | 3.953 ± 0.80532 | 5.643 ± 0.88921 | 6.61 |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. t1/2 for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants).
| hours | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plasma Decay Half-Life (t1/2): Single-Dose Analysis | 2.64 | 3.78 | 3.76 | 3.22 | 3.88 | 2.70 | 3.83 | 3.08 | 4.77 | 4.02 | 3.13 | 6.54 | 5.80 | 3.85 | — | — |
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL/F for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).
| milliliter/minute (mL/min) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Oral Clearance (CL/F): Multiple-Dose Analysis | 19.00 ± 10 | 17.70 ± 47 | 18.54 ± 49 | NA ± NA | 34.18 ± 61 | NA ± NA | NA ± NA | 30.49 ± 9 | 58.23 ± 42 | 49.49 ± 19 | 63.7 | NA ± NA | 90.56 ± 26 | 78.38 ± 12 | 85.87 ± 17 | 73.1 |
Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL/F for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning is reported (single-dose participants).
| mL/min | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Oral Clearance (CL/F): Single-Dose Analysis | 31.5 | 24.7 | 20.1 | 28.0 | 32.3 | 60.1 | 38.8 | 45.5 | 58.2 | 45.8 | 64.8 | 54.3 | 99.6 | 90.0 | — | — |
Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time. CLr for participants who received pregabalin from Day 1 to Day 8 morning is reported (multiple-dose participants).
| mL/min | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Renal Clearance (CLr): Multiple-Dose Analysis | — | 21.0 | — | — | 8.77 | — | 48.4 | 11.5 | — | 24.75 ± 88 | 55.9 | 36.9 | — | NA ± NA | 69.16 ± 39 | — |
Renal clearance is the volume of plasma from which the drug is completely removed by the kidney in a given amount of time. CLr for participants who received matching placebo from Day 1 to Day 7 and pregabalin on Day 8 morning was to be reported (single-dose participants).
| mL/min | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 1 to 23 Months) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 2 to 6 Years) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 7 to 11 Years) | Placebo, Pregabalin 1.25 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 2.5 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 5 mg/kg (Age Cohort: 12 to 16 Years) | Placebo, Pregabalin 7.5 mg/kg (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Renal Clearance (CLr): Single-Dose Analysis | — | — | — | — | — | — | — | — | — | — | — | 42.6 | — | 73.8 | — | — |
Analysis for severity of AEs was performed separately for double-blind and open-label treatment. AE = any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. AEs were classified as mild, moderate and severe based on severity assessment: Mild = no interference with participant's usual function; Moderate = some interference with participant's usual function; Severe = significant interference with participant's usual function. Treatment-emergent events for open-label treatment included events between Day 8 and 28 days after the open-label dose that were absent before treatment or that worsened relative to pretreatment state. Participants may experience more than 1 AE.
| adverse events | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Placebo (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Placebo (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Placebo (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) | Placebo (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mild | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Moderate | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Severe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | — | 0/3 (0%) | 1/3 (33.3%) |
| Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | — | 0/3 (0%) | 2/3 (66.7%) |
| Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | — | 0/3 (0%) | 1/3 (33.3%) |
| Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | — | 0/3 (0%) | 3/3 (100%) |
| Placebo (Age Cohort: 1 to 23 Months) | — | 0/4 (0%) | 2/4 (50%) |
| Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | — | 0/4 (0%) | 2/4 (50%) |
| Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | — | 0/3 (0%) | 1/3 (33.3%) |
| Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | — | 0/3 (0%) | 2/3 (66.7%) |
| Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | — | 0/3 (0%) | 2/3 (66.7%) |
| Placebo (Age Cohort: 2 to 6 Years) | — | 0/5 (0%) | 4/5 (80%) |
| Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | — | 0/3 (0%) | 2/3 (66.7%) |
| Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | — | 0/3 (0%) | 3/3 (100%) |
| Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | — | 0/2 (0%) | 2/2 (100%) |
| Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | — | 1/3 (33.3%) | 2/3 (66.7%) |
| Placebo (Age Cohort: 7 to 11 Years) | — | 1/5 (20%) | 2/5 (40%) |
| Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | — | 0/3 (0%) | 1/3 (33.3%) |
| Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | — | 0/3 (0%) | 1/3 (33.3%) |
| Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | — | 0/4 (0%) | 4/4 (100%) |
| Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) | — | 0/2 (0%) | 2/2 (100%) |
| Placebo (Age Cohort: 12 to 16 Years) | — | 0/3 (0%) | 0/3 (0%) |
| Event | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Placebo (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Placebo (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Placebo (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) | Placebo (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AtaxiaNervous system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 0/5 | 0/3 | 0/3 | 0/2 | 1/3 | 0/5 | 0/3 | 0/3 | 0/4 | 0/2 | 0/3 |
| SomnolenceNervous system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 0/5 | 0/3 | 0/3 | 0/2 | 1/3 | 0/5 | 0/3 | 0/3 | 0/4 | 0/2 | 0/3 |
| ConvulsionNervous system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 0/5 | 0/3 | 0/3 | 0/2 | 0/3 | 1/5 | 0/3 | 0/3 | 0/4 | 0/2 | 0/3 |
| Event | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Placebo (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Placebo (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Placebo (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) | Placebo (Age Cohort: 12 to 16 Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 1/3 | 0/3 | 0/5 | 0/3 | 0/3 | 0/2 | 2/3 | 0/5 | 0/3 | 0/3 | 2/4 | 1/2 | 0/3 |
| SomnolenceNervous system disorders | 0/3 | 2/3 | 0/3 | 2/3 | 2/4 | 1/4 | 1/3 | 0/3 | 0/3 | 0/5 | 2/3 | 1/3 | 0/2 | 1/3 | 0/5 | 1/3 | 0/3 | 0/4 | 1/2 | 0/3 |
| NauseaGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 0/5 | 0/3 | 0/3 | 0/2 | 0/3 | 0/5 | 0/3 | 0/3 | 0/4 | 1/2 | 0/3 |
| VomitingGastrointestinal disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/4 | 0/4 | 0/3 | 1/3 | 0/3 | 1/5 | 0/3 | 0/3 | 0/2 | 0/3 | 0/5 | 0/3 | 0/3 | 1/4 | 1/2 | 0/3 |
| Upper respiratory tract infectionInfections and infestations | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 1/5 | 0/3 | 0/3 | 1/2 | 0/3 | 0/5 | 0/3 | 0/3 | 0/4 | 0/2 | 0/3 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 0/5 | 0/3 | 0/3 | 1/2 | 0/3 | 0/5 | 0/3 | 0/3 | 0/4 | 0/2 | 0/3 |
| Balance disorderNervous system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 0/5 | 0/3 | 0/3 | 0/2 | 0/3 | 0/5 | 0/3 | 0/3 | 0/4 | 1/2 | 0/3 |
| LethargyNervous system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 1/4 | 0/3 | 0/3 | 0/3 | 1/5 | 0/3 | 0/3 | 1/2 | 0/3 | 1/5 | 0/3 | 0/3 | 0/4 | 0/2 | 0/3 |
| Psychomotor hyperactivityNervous system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 0/5 | 0/3 | 0/3 | 1/2 | 0/3 | 0/5 | 0/3 | 0/3 | 0/4 | 0/2 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 2/5 | 0/3 | 0/3 | 0/2 | 0/3 | 0/5 | 0/3 | 0/3 | 0/4 | 0/2 | 0/3 |
| Age, Continuous(years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Placebo (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Placebo (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Placebo (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) | Placebo (Age Cohort: 12 to 16 Years) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 1.2 ± 0.7 | 1.4 ± 0.5 | 0.7 ± 0.5 | 0.6 ± 0.1 | 1.6 ± 0.3 | 4.0 ± 0.8 | 2.9 ± 0.1 | 4.0 ± 1.7 | 3.9 ± 1.8 | 3.7 ± 1.0 | 9.3 ± 1.2 | 9.7 ± 2.3 | 10.0 ± 0.0 | 9.0 ± 1.0 | 9.2 ± 1.5 | 15.7 ± 0.6 | 13.7 ± 2.1 | 14.0 ± 1.8 | 15.5 ± 0.7 | 13.0 ± 1.7 | 6.9 ± 5.2 |
| Sex: Female, Male(Participants) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 5 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 10 mg/kg/Day (Age Cohort: 1 to 23 Months) | Pregabalin 15 mg/kg/Day (Age Cohort: 1 to 23 Months) | Placebo (Age Cohort: 1 to 23 Months) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 2 to 6 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 2 to 6 Years) | Placebo (Age Cohort: 2 to 6 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 7 to 11 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 7 to 11 Years) | Placebo (Age Cohort: 7 to 11 Years) | Pregabalin 2.5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 5 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 10 mg/kg/Day (Age Cohort: 12 to 16 Years) | Pregabalin 15 mg/kg/Day (Age Cohort: 12 to 16 Years) | Placebo (Age Cohort: 12 to 16 Years) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 1 | 2 | 2 | 4 | 2 | 1 | 1 | 3 | 2 | 1 | 0 | 0 | 4 | 2 | 1 | 0 | 0 | 3 | 32 |
| Male | 2 | 1 | 2 | 1 | 2 | 0 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 3 | 1 | 1 | 2 | 4 | 2 | 0 | 33 |
The record gives a start of Apr 2007, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →